NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION

QR Code

NEW OPPORTUNITIES IN TREATMENT OF CHRONIC HEART FAILURE WITH NORMAL EJECTION FRACTION

Aim. To evaluate aim worthiness and efficacy of the application of angiotensin type II receptor blockers (ARB) and calcium channel antagonists (CCA) in patients with early stages of chronic heart failure with normal ejection fraction (CHF-NEF) developed on the background of arterial hypertension and...

Full description

Saved in:

Bibliographic Details
Main Authors:	A. G. Dushina, R. A. Libis
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2015-08-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	chronic heart failure with normal ejection fraction calcium channel antagonists angiotensin ii receptor blockers
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/247
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Features of chronic heart failure depending on the left ventricular ejection fraction
by: A. G. Dushina, et al.
Published: (2019-03-01)

Beta-blockers in chronic heart failure with preserved left ventricular ejection fraction: is deprescribing possible?
by: V. D. Zakiev, et al.
Published: (2023-12-01)

The Effect of Angiotensin Receptor and Neprilysin Inhibitors on Quality of Life in Patients with Heart Failure with Reduced Ejection Fraction and Functional Mitral Regurgitation
by: A. S. Ryazanov, et al.
Published: (2023-01-01)

THE ROLE OF DIET AND PHYSICAL ACTIVITY IN THERAPY OF CARDIOVASCULAR PATIENTS WITH NORMAL EJECTION FRACTION
by: O. M. Drapkina, et al.
Published: (2017-04-01)

EFFECT OF ANGIOTENSIN-II RECEPTOR ANTAGONIST LOSARTAN AND ITS COMBINATION WITH DIURETICS ON MYOCARDIAL MORPHO-FUNCTIONAL CONDITIONS IN HYPERTENSIVE PATIENTS WITH LEFT VENTRICULAR HYPERTROPHY
by: S. N. Tolpygina, et al.
Published: (2016-01-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

Chronic heart failure with preserved ejection fraction: optimal therapy. Literature review
by: A. A. Kuzmenko, et al.
Published: (2022-10-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Biomarkers in the Pathogenesis of Heart Failure with Preserved as Well as Reduced Ejection Fraction: A Cross-sectional Study
by: Sowmiya Thiyagarajan, et al.
Published: (2025-06-01)

Features of phenotyping patients with heart failure with preserved ejection fraction
by: E. K. Serezhina, et al.
Published: (2023-09-01)

Phenotypic clusters in heart failure with preserved and mid-range ejection fraction: new data and perspectives
by: O. V. Tsygankova, et al.
Published: (2021-05-01)

Heart failure with preserved left ventricular ejection fraction – clinical perspectives
by: Małgorzata Niemiec, et al.
Published: (2025-07-01)

The effect of renin-angiotensin system blockers on aldosterone levels in patients with chronic heart failure with preserved ejection fraction
by: A. N. Shevelok
Published: (2020-12-01)

Markers of heart failure with preserved ejection fraction in patients with unexplained dyspnea
by: A. A. Ivanova, et al.
Published: (2023-11-01)

Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
by: A. A. Shchendrygina, et al.
Published: (2021-07-01)

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes
by: D. A. Lebedev, et al.
Published: (2020-11-01)

Characteristics of patients with chronic heart failure with mildly reduced ejection fraction: clinical and demographic aspect
by: M. T. Duishenalieva, et al.
Published: (2025-05-01)

New possibilities in pharmacotherapy for the heart failure with reduced ejection fraction treatment in patients with recent deterioration
by: I. V. Gribkova
Published: (2024-03-01)

Influence of aldosterone antagonists on markers of electrophysiological instability in patients with heart failure with mid-range ejection fraction after ST-segment elevation acute coronary syndrome in the short- and long-term periods
by: L. V. Shekhovtsova, et al.
Published: (2020-11-01)

Cardiorenal relationships in patients with chronic heart failure with preserved ejection fraction
by: Yu. N. Panina, et al.
Published: (2023-11-01)

ANGIOTENSIN RECEPTOR BLOCKERS WITH PLEIOTROPIC PROPERTIES: A NEW STANDARD IN CARDIOVASCULAR RISK MANAGEMENT AND TREATMENT OF HYPERTENSION
by: V. I. Podzolkov, et al.
Published: (2017-07-01)

Clinical and prognostic value of determining the level of neopterin in patients with chronic heart failure with preserved ejection fraction
by: O. S. Polunina, et al.
Published: (2018-10-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: TREATMENT IN CONDITIONS OF LIMITED EVIDENCE
by: S. G. KANORSKIĬ, et al.
Published: (2018-10-01)

Effect of therapy on the dynamics of collagen metabolism markers in older patients with heart failure with mid-range ejection fraction and coronary artery disease
by: O. A. Osipova, et al.
Published: (2020-11-01)

Heart rate-lowering antianginal medications: what determines their choice?
by: Yu. M. Lopatin
Published: (1970-01-01)

Prediction model of rehospitalization and mortality in heart failure patients with preserved and mildly reduced ejection fraction: the AD2NNER risk score
by: Flavia-Mihaela Stoiculescu, et al.
Published: (2025-07-01)

Features of structural and geometric remodeling of the heart and changes in the diastolic filling of the heart in patients with chronic heart failure of ischemic genesis with preserved left ventricular ejection fraction
by: V. A. Lysenko, et al.
Published: (2021-03-01)

TREATMENT OF HYPERTENSION IN PREGNANCY: GUIDELINES AND CLINICAL EXPERIENCE
by: O. V. Gaisenok, et al.
Published: (2015-09-01)

Prognostic significance of NT-proBNP and sST2 in patients with heart failure with preserved and mildly reduced ejection fraction
by: V. I. Podzolkov, et al.
Published: (2023-10-01)

TO THE 110-TH ANNIVERSARY OF RENIN FINDING. FIGHT OF TITANS: ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND SARTANS
by: L. N. Malay, et al.
Published: (2016-01-01)

Heart failure with improved ejection fraction in patients with tachycardia-induced cardiomyopathy: a case report
by: E. A. Pravkina, et al.
Published: (2023-07-01)

The impact of glomerular filtration rate on short-term outcome in elderly patients with heart failure with preserved ejection fraction
by: Giuseppe Delli Carpini, et al.
Published: (2025-07-01)

Effect of Medical Therapy on Reducing the Risk of Pacing‐Induced Cardiomyopathy
by: Mahdi S. Agha, et al.
Published: (2025-07-01)

The use of mineralocorticoid antagonists in chronic heart failure
by: Andrea Szegedi, et al.
Published: (2025-07-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Low-intensity inflammation as a manifestation of comorbidity and a factor in the unfavorable clinical course of heart failure with preserved ejection fraction
by: K. N. Vitt, et al.
Published: (2024-03-01)

Predictors of unfavorable progression and prognosis in patients with heart failure with preserved left ventricular ejection fraction
by: M. S. Sobolevskaya, et al.
Published: (2024-12-01)

Chronic Heart Failure with Preserved Ejection Fraction in A Comorbid Patient: Issues in Verification of A «Difficult» Diagnosis
by: O. V. Ponomareva, et al.
Published: (2025-05-01)